tradingkey.logo
tradingkey.logo
Buscar

LeonaBio Ord Shs

LONA
Añadir a la lista de seguimiento
3.470USD
-0.260-6.97%
Cierre 11-13 16:00(ET)
32.69MCap. mercado
PérdidaP/E TTM

Acerca de LeonaBio Ord Shs Compañía

LeonaBio, Inc., formerly Athira Pharma, Inc., is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). The Company's lead drug candidates, lasofoxifene and ATH-1105, are novel, small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. ATH-1105 is a novel, orally available, brain-penetrant, next-generation small-molecule drug candidate designed to positively modulate the neurotrophic HGF system for potential treatment of neurodegenerative diseases, including ALS, Alzheimer's disease, and Parkinson's disease. Lasofoxifene is a novel, nonsteroidal SERM with a binding profile, designed to confer potent activity against both wild-type and mutant estrogen receptors, including the clinically significant ESR1 mutations.

Perfil de LeonaBio Ord Shs

Símbolo de cotización- -
Nombre de la empresa- -
Fecha de salida a bolsa- -
Director ejecutivo- -
Número de empleados- -
Tipo de seguridad- -
Fin del año fiscal- -
Dirección- -
Ciudad- -
Bolsa de valores- -
País- -
Código postal- -
Teléfono- -
Sitio Web- -
Símbolo de cotización- -
Fecha de salida a bolsa- -
Director ejecutivo- -

Ejecutivos de LeonaBio Ord Shs

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Mark James Litton, Ph.D.
Dr. Mark James Litton, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
59.89K
--
Dr. Mark James Litton, Ph.D.
Dr. Mark James Litton, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
59.89K
--
Dr. Mark James Litton, Ph.D.
Dr. Mark James Litton, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
59.89K
--
Dr. Kevin Church, Ph.D.
Dr. Kevin Church, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
25.18K
+17.86%
Dr. Kevin Church, Ph.D.
Dr. Kevin Church, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
25.18K
+17.86%
Dr. Kevin Church, Ph.D.
Dr. Kevin Church, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
25.18K
+17.86%
Mr. Mark Worthington
Mr. Mark Worthington
Chief Compliance Officer, General Counsel, Company Secretary
Chief Compliance Officer, General Counsel, Company Secretary
18.38K
--
Mr. Mark Worthington
Mr. Mark Worthington
Chief Compliance Officer, General Counsel, Company Secretary
Chief Compliance Officer, General Counsel, Company Secretary
18.38K
--
Mr. Mark Worthington
Mr. Mark Worthington
Chief Compliance Officer, General Counsel, Company Secretary
Chief Compliance Officer, General Counsel, Company Secretary
18.38K
--
Dr. Javier San Martin, M.D.
Dr. Javier San Martin, M.D.
Chief Medical Officer
Chief Medical Officer
15.89K
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Mark James Litton, Ph.D.
Dr. Mark James Litton, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
59.89K
--
Dr. Mark James Litton, Ph.D.
Dr. Mark James Litton, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
59.89K
--
Dr. Mark James Litton, Ph.D.
Dr. Mark James Litton, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
59.89K
--
Dr. Kevin Church, Ph.D.
Dr. Kevin Church, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
25.18K
+17.86%
Dr. Kevin Church, Ph.D.
Dr. Kevin Church, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
25.18K
+17.86%
Dr. Kevin Church, Ph.D.
Dr. Kevin Church, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
25.18K
+17.86%

Preguntas frecuentes

¿Quiénes son los cinco principales accionistas de LeonaBio Ord Shs?

Los cinco principales accionistas de LeonaBio Ord Shs son: Dr. Mark James Litton, Ph.D.

¿Cuántas instituciones poseen acciones de LeonaBio Ord Shs (LONA)?

A fecha de 2026Q1, 120 instituciones poseen acciones de LeonaBio Ord Shs, con un valor de mercado combinado de aproximadamente 6.66M, lo que representa el 70.97% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 2319889.00.
tradingkey.logo
Advertencia de Riesgo: Nuestro sitio web y aplicación móvil solo proporcionan información general sobre ciertos productos de inversión. Finsights no proporciona, y la provisión de dicha información no debe interpretarse como que Finsights proporciona, asesoramiento financiero o recomendación para cualquier producto de inversión.
Los productos de inversión están sujetos a riesgos de inversión significativos, incluida la posible pérdida del monto principal invertido y pueden no ser adecuados para todos. El rendimiento pasado de los productos de inversión no es indicativo de su rendimiento futuro.
Finsights puede permitir que anunciantes o afiliados de terceros coloquen o entreguen anuncios en nuestro sitio web o aplicación móvil o en cualquier parte de los mismos y puede ser compensado por ellos en función de su interacción con los anuncios.
© Derechos de autor: FINSIGHTS MEDIA PTE. LTD. Todos los derechos reservados.